GlassScriptPhysician profile
Loc Trong Le
NPI 1194710517
$10,719.40
in general payments reported to CMS, 2019-2025
36 companies · $2,509 in 2025
The $2,509 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $643 · 2021: $1,123 · 2022: $1,619 · 2023: $1,978 · 2024: $1,524 · 2025: $2,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,934 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,934.26 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,711.05 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,285.23 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $954.66 | 2019-2024 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $832.14 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $710.34 | 2019-2025 | |
| Celgene Corporation | $598.79 | 2021-2024 | Zeposia |
| Genzyme Corporation | $407.47 | 2023-2025 | |
| Madrigal Pharmaceuticals | $275.29 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $210.00 | 2022-2024 | Dupixent |
| Ardelyx, INC. | $192.65 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $141.90 | 2020-2023 | |
| Redhill Biopharma INC. | $133.54 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $118.35 | 2019-2023 | Linzess |
| Ipsen Biopharmaceuticals, INC | $117.95 | 2025 | Iqirvo |
| Qol Medical, LLC | $117.10 | 2019-2025 | Sucraid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $113.80 | 2021 | |
| Ferring Pharmaceuticals INC. | $109.63 | 2019-2021 | |
| Amgen INC. | $106.39 | 2020-2023 | Amjevita, Avsola |
| Merck Sharp & Dohme LLC | $89.34 | 2019-2024 | Dificid |
| Aimmune Therapeutics, INC. | $80.39 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $63.89 | 2019-2023 | Ocaliva |
| Gilead Sciences, INC. | $63.89 | 2024-2025 | |
| Medtronic, INC. | $40.93 | 2022 | |
| Organon LLC | $36.39 | 2023 | Hadlima, Renflexis |
| Romark Laboratories, Lc | $34.81 | 2019 | |
| Allergan, INC. | $23.20 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $23.17 | 2024 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $20.74 | 2022 | |
| Shire North American Group INC | $19.30 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.98 | 2023 | Givlaari |
| Celltrion USA INC. | $15.49 | 2025 | Vegzelma |
| Dova Pharmaceuticals | $15.02 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.67 | 2025 | Voquezna |
| Lilly USA, LLC | $13.57 | 2024 | Omvoh |
| Daiichi Sankyo INC. | $12.34 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loc Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.